PURETECH FOUNDED ENTITY SEAPORT THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 2A CLINICAL TRIAL EVALUATING GLYPHAGO™ IN PATIENTS WITH GENERALIZED ANXIETY DISORDER AND SLEEP DISTURBANCE

Reuters · 1d ago

Please log in to view news